DE60042215D1 - Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit - Google Patents

Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit

Info

Publication number
DE60042215D1
DE60042215D1 DE60042215T DE60042215T DE60042215D1 DE 60042215 D1 DE60042215 D1 DE 60042215D1 DE 60042215 T DE60042215 T DE 60042215T DE 60042215 T DE60042215 T DE 60042215T DE 60042215 D1 DE60042215 D1 DE 60042215D1
Authority
DE
Germany
Prior art keywords
methods
symptoms
disease
compositions
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60042215T
Other languages
English (en)
Inventor
Jodi Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Research Group LLC
Original Assignee
Alpha Research Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Research Group LLC filed Critical Alpha Research Group LLC
Application granted granted Critical
Publication of DE60042215D1 publication Critical patent/DE60042215D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60042215T 1999-07-13 2000-07-13 Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit Expired - Fee Related DE60042215D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14376799P 1999-07-13 1999-07-13
US17505100P 2000-01-07 2000-01-07
US20214000P 2000-05-05 2000-05-05
PCT/US2000/040385 WO2001003649A2 (en) 1999-07-13 2000-07-13 Compositions and methods for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
DE60042215D1 true DE60042215D1 (de) 2009-06-25

Family

ID=27385980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042215T Expired - Fee Related DE60042215D1 (de) 1999-07-13 2000-07-13 Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit

Country Status (8)

Country Link
US (1) US6417177B1 (de)
EP (1) EP1261340B1 (de)
JP (1) JP2004500331A (de)
AT (1) ATE431141T1 (de)
AU (1) AU779955B2 (de)
CA (1) CA2416233A1 (de)
DE (1) DE60042215D1 (de)
WO (1) WO2001003649A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581167A4 (de) * 2002-07-09 2008-10-29 Alpha Res Group Llc Zusammensetzungen und verfahren zur behandlung von parkinson und tardiver dyskinesie
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
CN101238370A (zh) * 2003-01-27 2008-08-06 贝勒医学院 通过检测脑毒素诊断和监控神经系统疾病的方法
ES2405404T3 (es) * 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
AU2005271192B2 (en) * 2004-08-13 2011-11-17 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
UA95993C2 (ru) * 2004-08-13 2011-09-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
US20090035797A1 (en) * 2004-10-15 2009-02-05 Hancock William S Detection of Disease Associated Proteolysis
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
EP1988875A2 (de) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modifizierte freisetzungsformulierung
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
JP2009527478A (ja) * 2006-02-16 2009-07-30 ザ マクレーン ホスピタル コーポレーション パーキンソン病の治療のための方法と組成物
US7863295B2 (en) 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
US20100135908A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
US10370395B2 (en) 2015-01-02 2019-08-06 University Of Vermont And State Agricultural College Cymanquine compounds and derivatives thereof and uses thereof
KR101983850B1 (ko) * 2017-11-06 2019-05-29 동아대학교 산학협력단 탈미엘린화 유발 신경계 질환의 예방 또는 치료용 의약 조성물 및 건강기능식품
JP7473565B2 (ja) * 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法
CN113350343A (zh) * 2020-03-06 2021-09-07 华南理工大学 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN113350344A (zh) * 2020-03-06 2021-09-07 华南理工大学 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
US20230416786A1 (en) 2020-11-30 2023-12-28 Cellectis Sa Use of aminoquinoline compounds for higher gene integration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498187A1 (fr) 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
CA2133620A1 (en) 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
HU215830B (hu) 1994-04-19 2001-05-28 Neurosearch A/S Tropán-2-aldoxim-származékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek előállítása és alkalmazása gyógyszerkészítmények előállítására
US5624938A (en) 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
ATE203519T1 (de) 1995-11-16 2001-08-15 Hoffmann La Roche Chinolinderivate als antimalariamittel
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs

Also Published As

Publication number Publication date
JP2004500331A (ja) 2004-01-08
CA2416233A1 (en) 2001-01-18
EP1261340A2 (de) 2002-12-04
AU779955B2 (en) 2005-02-24
ATE431141T1 (de) 2009-05-15
US6417177B1 (en) 2002-07-09
EP1261340A4 (de) 2005-05-04
WO2001003649A2 (en) 2001-01-18
AU7386500A (en) 2001-01-30
EP1261340B1 (de) 2009-05-13
WO2001003649A3 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
DE60042215D1 (de) Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
ATE446744T1 (de) Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей
HK1072541A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
ATE451368T1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
ATE302025T1 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
ATE413177T1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE60005952T8 (de) Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
HUP0300043A2 (en) Method and composition for the treatment of pain
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
EP1260221A3 (de) Kombinationsbehandlung für Depression und Angstzustände
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
ATE296640T1 (de) Methode und mittel zur behandlung eines post- poliosyndroms

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee